Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A comparison study of staging systems for bone sarcomas.

Robert K Heck1, G Scott Stacy, Michael J Flaherty

  • 1Campbell Clinic/University of Tennessee, Department of Orthopaedics, Memphis, TN 38104, USA. rheck@campbellclinic.com

Clinical Orthopaedics and Related Research
|November 13, 2003
PubMed
Summary

This study compared two bone sarcoma staging systems: the American Joint Committee on Cancer (AJCC) and the Musculoskeletal Tumor Society (MVS) systems. Neither system showed a significant advantage in predicting patient prognosis in this retrospective analysis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue With EWSR1/FUS::NFATC2 Fusions: A Review of Clinicopathologic Characteristics, Differential Diagnoses, and Patient Management.

Archives of pathology & laboratory medicine·2025
Same author

Survival differences in pulmonary metastatic osteosarcoma between pediatric and adult institutions.

Journal of pediatric surgery·2025
Same author

ABOS Partnerships and Collaboration.

The Journal of bone and joint surgery. American volume·2025
Same author

County-level socioeconomic, race-ethnicity, household, and infrastructure vulnerability associations with bone cancer treatment and prognosis in the US.

Annals of epidemiology·2025
Same author

Surgeon perspectives on a virtual reality platform for preoperative planning in complex bone sarcomas.

Journal of orthopaedics·2024
Same author

The History of Academic Leadership Education in Orthopaedic Surgery.

JB & JS open access·2024

Area of Science:

  • Orthopedic Oncology
  • Cancer Staging Research
  • Sarcoma Treatment Evaluation

Background:

  • Accurate prognostic staging is crucial for guiding treatment decisions in bone sarcomas.
  • Existing staging systems, including the Musculoskeletal Tumor Society (MVS) and the American Joint Committee on Cancer (AJCC), aim to stratify patients based on predicted outcomes.
  • Comparative analysis of these systems is essential to determine their relative effectiveness.

Purpose of the Study:

  • To evaluate the prognostic significance of the new American Joint Committee on Cancer (AJCC) staging system in comparison to the Musculoskeletal Tumor Society (MVS) staging system for bone sarcomas.
  • To determine if one staging system offers a superior ability to predict patient survival.
  • To assess the prognostic value of specific stage groupings within each system.

Related Experiment Videos

Main Methods:

  • A retrospective study was conducted involving 250 patients diagnosed with bone sarcomas.
  • Patient data was analyzed to compare survival rates across different stages defined by both the MVS and AJCC staging systems.
  • Statistical analysis was performed to identify significant differences in survival between various stage categories within each system.

Main Results:

  • The Musculoskeletal Tumor Society (MVS) system demonstrated significant survival differences between Stage I, II, and III disease, but not between substages (e.g., I-A vs. I-B).
  • The American Joint Committee on Cancer (AJCC) system showed significant survival differences between Stage I, II, and IV disease, but not between its substages (e.g., I-A vs. I-B, II-A vs. II-B, IV-A vs. IV-B).
  • This study did not find a statistically significant advantage for either the AJCC or MVS staging system in predicting prognosis for bone sarcoma patients, likely due to the sample size.

Conclusions:

  • Both the AJCC and MVS staging systems provide some prognostic information for bone sarcomas.
  • Neither staging system demonstrated a clear superiority over the other in predicting patient outcomes within this study cohort.
  • Further research with larger patient populations is warranted to definitively compare the prognostic capabilities of the AJCC and MVS staging systems for bone sarcomas.